Stock Price Quote

PANACEA BIOTEC LTD.

NSE : PANACEABIOBSE : 531349ISIN CODE : INE922B01023Industry : Pharmaceuticals & DrugsHouse : Soshil Kumar Jain
BSE447.65-4.2 (-0.93 %)
PREV CLOSE ( ) 451.85
OPEN PRICE ( ) 464.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 30924
TODAY'S LOW / HIGH ( )443.15 464.00
52 WK LOW / HIGH ( )112.7 489
NSE447.75-3 (-0.67 %)
PREV CLOSE( ) 450.75
OPEN PRICE ( ) 464.90
BID PRICE (QTY) 447.75 (87)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 194067
TODAY'S LOW / HIGH( ) 441.55 464.90
52 WK LOW / HIGH ( )112.35 490.55
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
Rajesh Jain - Chairman Rajesh Jain - Managing Director
Registered Office

Address Ambala - Chandigarh Highway,,,
Lalru,
Punjab-140501

Phone 01762- 505900

Email companysec@panaceabiotec.com

Website www.panaceabiotec.com

Registrars Details
Skyline Financial Services Pvt Ltd
D-153/A, 1st Floor,Okhla Industrial Area,Phase - I,New Delhi
Listing : BSE, NSE

NEWS

12Mar Clarification On Movement In Price
Please find attached Company''s response dated March 12, 2025 on Clarifi..
11Mar Clarification sought from Panacea Bio
The Exchange has sought clarification from Panacea Biotec Ltd on March 1..
31Jan Panacea Biotec informs about board mee
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosur..
03Jan Panacea Biotec’s arm launches baby dia
Panacea Biotec’s wholly owned subsidiary -- Panacea Biotec Pharma has la..
28Dec Panacea Biotec’s arm makes further inv
Panacea Biotec’s material subsidiary -- Panacea Biotec Pharma (PBPL) has..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit96.499999999999935.4999999999997
Gross Profit 96.4999999999999 42.0999999999997
Operating Profit 187.1390.8
Net Sales 1084.33596

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  5876.90 (3.05%)
M.Cap ( in Cr)13534.87
Mankind Pharma (BSE)
peergroup  2416.05 (7.57%)
M.Cap ( in Cr)99681.04
Procter&Gamble Healt (BSE)
peergroup  5486.15 (2.87%)
M.Cap ( in Cr)9106.67
Neuland Laboratories (BSE)
peergroup  11818.40 (1.21%)
M.Cap ( in Cr)15162.88
Astrazeneca Pharma I (BSE)
peergroup  8521.50 (1.55%)
M.Cap ( in Cr)21303.75

Shareholding Pattern

PROMOTERS 72.49%
NON-INSTITUTION 25.97%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Panacea Biotec Ltd.

Panacea Biotec Ltd. was incorporated in the year 1984. Its today's share price is 447.65. Its current market capitalisation stands at Rs 2741.89 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3604.1 Cr and Total Income of Rs.3845.11 Cr. The company's management includes Narotam Kumar Juneja, Mukul Gupta, Manjula Upadhyay, Ambika Sharma, Ankesh Jain, Sandeep Jain, Rajesh Jain, Rajesh Jain, Vinod Goel.

It is listed on the BSE with a BSE Code of 531349 , NSE with an NSE Symbol of PANACEABIO and ISIN of INE922B01023. It's Registered office is at Ambala - Chandigarh Highway,,Lalru-140501, Punjab. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are SR Batliboi & Co LLP, Walker Chandiok & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.